What are the differences between doxylamine and diphenhydramine regarding indications, dosing, efficacy, side effects, and safety in adults, including use for allergic symptoms versus insomnia and use in pregnancy?

Doxylamine vs Diphenhydramine: Clinical Comparison

Neither doxylamine nor diphenhydramine should be routinely used for chronic insomnia in adults, as the American Academy of Sleep Medicine explicitly recommends against diphenhydramine (and provides no recommendation for doxylamine due to lack of evidence), but for occasional insomnia or nausea/vomiting in pregnancy, doxylamine has superior safety data and should be preferred. 1

For Insomnia Treatment

Efficacy Evidence

Diphenhydramine lacks clinically meaningful efficacy for insomnia. The 2017 American Academy of Sleep Medicine guideline provides a WEAK recommendation AGAINST using diphenhydramine 50 mg for sleep onset and sleep maintenance insomnia 1. The evidence shows:

• Sleep latency reduction of only 2.47 minutes vs placebo (below clinical significance threshold)
• Total sleep time increase of only 17.86 minutes (below the 20-minute clinical significance threshold)
• No clinically significant improvements in wake after sleep onset, sleep quality, or sleep efficiency
• Quality of evidence rated as LOW due to imprecision and publication bias 1

Doxylamine has minimal comparative data. Small trials showed no major efficacy difference between doxylamine and benzodiazepines, but robust placebo-controlled trials are lacking 2. A 2015 systematic review concluded that diphenhydramine and valerian "lack robust clinical evidence supporting efficacy and safety" 3.

Safety Concerns for Insomnia Use

Both agents carry significant risks in older adults:

• The 2015 Beers Criteria explicitly recommends that adults ≥65 years avoid both diphenhydramine and doxylamine due to anticholinergic effects 4, 5
• Common adverse effects include daytime drowsiness, altered vigilance, cognitive impairment, falls, and fractures 2
• Anticholinergic effects (confusion, urinary retention, constipation) are particularly problematic in elderly patients 6
• 59% of older adults inappropriately use these medications chronically despite indications only for occasional use 4

Dosing for Insomnia (When Occasionally Used Despite Recommendations)

• Diphenhydramine: 25-50 mg orally at bedtime 6
• Doxylamine: 25 mg orally at bedtime (typical OTC dose)

For Allergic Conditions

Both are first-generation H1-antihistamines with similar efficacy for allergic rhinitis, urticaria, and allergic reactions 7. Diphenhydramine is more commonly used and studied for acute allergic reactions including anaphylaxis (as adjunctive therapy) 7.

Dosing for Allergies

• Diphenhydramine: 25-50 mg every 4-6 hours (maximum 300 mg/day) 6
• Doxylamine: Primarily marketed for sleep, not typically used for allergies

Use in Pregnancy

Doxylamine is strongly preferred in pregnancy and is the only antihistamine with robust safety data for this population.

Pregnancy Safety Profile

Doxylamine (combined with pyridoxine as Xonvea®/Diclegis®) is recommended as FIRST-LINE treatment for nausea and vomiting in pregnancy by the 2024 BJOG guideline 8. Key evidence:

• Cochrane review reports no increased risk of congenital malformations or adverse pregnancy outcomes 8
• Case-control studies provide reassuring data on doxylamine use during pregnancy 2
• Classified as Grade A recommendation (highest quality evidence) 8

Diphenhydramine has concerning pregnancy data:

• Case-control studies show a statistical link between benzodiazepine use (and by extension, sedative antihistamines) in early pregnancy and birth defects such as cleft lip 2
• While not definitively proven, the risk-benefit profile is less favorable than doxylamine
• FDA labeling advises consulting healthcare professional before use if pregnant 6

Pregnancy Dosing

• Doxylamine/pyridoxine (Xonvea®): Delayed-release formulation preferred for stable blood levels 8
• Use as directed for nausea/vomiting of pregnancy

Pharmacokinetic Differences

The agents have distinct pharmacokinetic profiles 9:

• Doxylamine: Elimination half-life ~10 hours, peak concentration at 1.9-2.4 hours
• Diphenhydramine: Elimination half-life ~5-6 hours, peak concentration at 2.2-2.7 hours

Doxylamine's longer half-life may provide better coverage for early morning awakening but increases risk of next-day sedation 10.

Clinical Algorithm for Selection

For nausea/vomiting in pregnancy:

• Use doxylamine (with pyridoxine) as first-line 8

For occasional insomnia in non-pregnant adults <65 years:

• Avoid both agents if possible; use cognitive-behavioral therapy for insomnia (CBT-I) first
• If pharmacotherapy needed occasionally: melatonin has better evidence than either antihistamine 3, 11
• If antihistamine must be used: doxylamine may have slight advantage for early morning awakening due to longer half-life 10

For adults ≥65 years with insomnia:

• Avoid both agents entirely per Beers Criteria 4, 5
• Consider melatonin (prolonged-release formulation) which has most consistent beneficial effects with favorable tolerability 3

For acute allergic reactions:

• Use diphenhydramine (more established for this indication) 7

Critical Pitfalls to Avoid

1. Do not use either agent for chronic insomnia - efficacy is not established beyond 1-2 weeks, and tolerance develops rapidly 1, 2
2. Do not prescribe to older adults - high risk of falls, cognitive impairment, and anticholinergic toxicity 4, 5
3. Warn about next-day impairment - both cause daytime drowsiness affecting driving and machinery operation 6
4. Avoid combining with alcohol or other sedatives - synergistic CNS depression 6
5. In pregnancy, choose doxylamine over diphenhydramine when antihistamine needed 8, 2